Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemiaFootnote^*
* Presented in part at the 2015 American Society of Hematology Annual Meeting, Orlando, FL, December 5–8, 2015

Matthew S. DavidsDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Haesook T. KimBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Lijian YuDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Guadalupe De MaeyerDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Mikaela McDonoughDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Alexander R. VartanovDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Rachael LangeyDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Stacey M. FernandesDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Jeffrey M. HellmanDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Karen FrancoeurDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Jon ArnasonDepartment of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USAView further author information

Eric D. JacobsenDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Ann S. LaCasceDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

David C. FisherDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; View further author information

Jennifer R. BrownDepartments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Correspondence[email protected]
View further author information

show all

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (2)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Citations (2)

Articles from other publishers (2)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date